- Phase III CANOPY-2 trial did not meet primary endpoint of overall survival in patients with advanced or metastatic non-small cell lung cancer whose cancer progressed while on or after previous treatments1
- Canakinumab development program continues; two Phase III non-small cell lung cancer clinical trials are ongoing in first-line and adjuvant settings2,3
- The CANOPY clinical trial program is designed to help answer critical questions about the role …
The COVID-19 pandemic created a number of different challenges for the patient community. Through those challenges, however, came opportunities to utilise digital engagement, and an accelerated use of digital tools. Participants of the European Patient Innovation Summit (EPIS) explored the positive and negative aspects of digital engagement during the COVID-19 pandemic at EPIS 2020 and made recommendations on how patients can continue to benefit from digital engagement in future.
The positive impact of these digital tools has been that they help patients …
The COVID-19 pandemic created a number of different challenges for the patient community. Through those challenges, however, came opportunities to utilise digital engagement, and an accelerated use of digital tools. Participants of the European Patient Innovation Summit (EPIS) explored the positive and negative aspects of digital engagement during the COVID-19 pandemic at EPIS 2020 and made recommendations on how patients can continue to benefit from digital engagement in future.
The positive impact of these digital tools has been that they help patients …
At Novartis, we believe in gender equity. We continue to choose to challenge inequity, including through our public pledge with the Equal Pay International Coalition (EPIC) to achieve gender balance in management and further improve our pay equity and transparency processes by 2023.
This International Women’s Day, we want to celebrate our progress while continuing to challenge ourselves and others to strive for meaningful change. We asked employees to recognize role models who …
At Novartis, we believe in gender equity. We continue to choose to challenge inequity, including through our public pledge with the Equal Pay International Coalition (EPIC) to achieve gender balance in management and further improve our pay equity and transparency processes by 2023.
This International Women’s Day, we want to celebrate our progress while continuing to challenge ourselves and others to strive for meaningful change. We asked employees to recognize role models who …
At Novartis, we believe in gender equity. We continue to choose to challenge inequity, including through our public pledge with the Equal Pay International Coalition (EPIC) to achieve gender balance in management and further improve our pay equity and transparency processes by 2023.
This International Women’s Day, we want to celebrate our progress while continuing to challenge ourselves and others to strive for meaningful change. We asked employees to recognize role models who …
- Shannon Klinger, Chief Legal Officer, to leave Novartis on March 15, 2021
- Thomas Kendris appointed Chief Legal Officer ad interim
Basel, March 5, 2021 — Novartis announced today that Shannon Thyme Klinger, Chief Legal Officer, has decided to resign from Novartis and return to the US to take an executive role at a biotechnology company. Ms. Klinger will step down from the Executive Committee of Novartis (ECN), effective March 15, 2021.
Thomas N. Kendris, currently Global Head Litigation and US Country President …
- Novartis to support global supply of another COVID-19 vaccine, leveraging manufacturing capacity and capabilities to help address pandemic.
- Novartis plans to manufacture the mRNA and bulk drug product of the CVnCoV vaccine candidate for up to 50 million doses by the end of 2021 and up to a further 200 million doses in 2022. Delivery from manufacturing site in Kundl, Austria expected to start in summer 2021.
- One of several agreements Novartis is reviewing on a global basis to help …
- Shareholders approve 24th consecutive dividend increase to CHF 3.00 (+1.7%) per share for 2020; representing a 3.8% yield1 and approximately 63% payout of free cash flow
- Shareholders confirm Dr. Joerg Reinhardt as Chairman of the Board of Directors as well as all other members who stood for re-election
- Shareholders approve all other proposals of the Board of Directors, including the 2020 Compensation Report in an advisory vote, as well as the future Board and Executive …
Cells have a built-in search and delete function. The existence of such a system came as a surprise 30 years ago, when researchers experimenting with petunias discovered it accidentally.
Today, however, scientists are wielding that capability as powerful medicine.
Medicines that leverage this search and delete system are designed to block the production of disease-related proteins by targeting RNA, the instructions normally used by cells to build proteins. This new type of therapeutic has the potential to interrupt almost any disease process in the body. Novartis is developing …
Follow us on Facebook
ADDRESS – ZIMBABWE
Suite 204, Block 1
Long Cheng Plaza
Mutley Bend, Belvedere
Harare, Zimbabwe
ADDRESS – ZAMBIA
Plot 43504
Apex Chalala
Off Kasama Road
Lusaka Zambia